Safety Analysis of Adverse Events of Ultrasound Contrast Agent Lumason/SonoVue in 49,100 Patients.

This study assessed the incidence of mild, moderate and severe adverse events (AEs) and examined their association with age, sex, body region examined, time to event and duration of the AE(s) in a large cohort of patients who underwent contrast-enhanced ultrasound (CEUS) with Lumason/SonoVue. In this retrospective observational study, 49,100 patients who underwent CEUS were analyzed. Forty-three (0.088%) patients experienced AEs, with 23 (0.047%) patients experiencing mild AEs, 13 (0.026%) experiencing moderate AEs and 7 (0.014%) experiencing severe AEs. No fatal event occurred. There was no age- or sex-related difference in the incidence of the AE(s) (p = 0.158 and p = 0.474). Inpatients (0.17%) more often experienced AEs than outpatients (0.06%, p = 0.003). The mean time to event for mild and moderate AEs was 14.50 ± 6.96 and 15.75 ± 10.40 min, respectively, whereas that for severe AEs was 1.89 ± 1.21 min after the injection. The remission time for mild and moderate AEs was approximately 30-40 min, and all patients with severe AEs recovered within 12 h. Twenty-one (48.8%) patients received medical treatment. In summary, Lumason/SonoVue has a good safety profile with a low incidence of AEs, most of which are mild with a short time to event and duration.

The nickel phosphate rods derived from Ni-MOF with enhanced electrochemical activity for non-enzymatic glucose sensing.

In this work, spherical Ni-based metal-organic frameworks (Ni-MOFs) were used as precursors for preparing nanorod-like nickel phosphate (r-NiPO) with enhanced electro-catalytic properties in detection of glucose. It was found that the addition of nickel ion has a profound effect on construction of nickel phosphate with flower-like, rod-like, and ribbon-like structure in presence of H2PO2-. The r-NiPO consisted of multiple phases of nickel phosphate showed porous, interconnected structure and abundant active Ni(II)/Ni(III) pairs, which was beneficial to facilitate glucose oxidation. In comparison with Ni-MOF, r-NiPO exhibited the superior electrocatalytic property on oxidation of glucose because of the exposing more active Ni sites in r-NiPO than that of Ni-MOF precursor. r-NiPO modified glassy carbon electrode (r-NiPO/GCE) showed a good linear response to glucose from 1.0 µM to 3.0 mM with a high sensitivity of 3169 µA mM-1 cm-2. In addition, r-NiPO/GCE can be used to detect glucose in human serum with satisfactory recoveries (90-97%).